Hikma Pharmaceuticals (LON:HIK) Sets New 52-Week Low - Here's What Happened

Key Points

• Hikma Pharmaceuticals (LON:HIK) reached a new 52-week low, trading as low as GBX 1,616 ($21.91) amid increasing investor concerns, and last trading at GBX 1,625.53.
• Analyst ratings show mixed sentiment, with Jefferies Financial reiterating a "buy" with a target of GBX 2,600, while Deutsche Bank and JPMorgan Chase lowered their price targets significantly.
• Insider transactions have occurred, including a purchase of 200,000 shares by Mazen Darwazah at an average price of GBX 1,756 per share, indicating insider confidence amidst stock price declines.

Hikma Pharmaceuticals PLC (LON:HIK - Get Free Report) shares reached a new 52-week low on Monday . The company traded as low as GBX 1,616 ($21.90) and last traded at GBX 1,625.53 ($22.03), with a volume of 501941 shares traded. The stock had previously closed at GBX 1,632 ($22.12).

Wall Street Analyst Weigh In

A number of research analysts recently commented on the company. JPMorgan Chase & Co. decreased their price target on Hikma Pharmaceuticals from GBX 2,600 to GBX 2,500 and set an "overweight" rating on the stock in a research report on Friday, August 8th. Jefferies Financial Group restated a "buy" rating and issued a GBX 2,600 price target on shares of Hikma Pharmaceuticals in a research report on Thursday, August 7th. Finally, Deutsche Bank Aktiengesellschaft decreased their price target on Hikma Pharmaceuticals from GBX 3,100 to GBX 2,850 and set a "buy" rating on the stock in a research report on Tuesday, August 12th. Four research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, Hikma Pharmaceuticals has a consensus rating of "Buy" and a consensus target price of GBX 2,627.50.

Hikma Pharmaceuticals Stock Performance

The company has a debt-to-equity ratio of 55.82, a current ratio of 1.66 and a quick ratio of 1.27. The stock has a 50-day simple moving average of GBX 1,832.79 and a 200-day simple moving average of GBX 1,948.23. The stock has a market cap of £3.58 billion, a P/E ratio of 967.66, a PEG ratio of 2.38 and a beta of 0.41.

Insider Activity

In other news, insider Mazen Darwazah purchased 14,000 shares of Hikma Pharmaceuticals stock in a transaction dated Tuesday, September 16th. The shares were bought at an average cost of GBX 1,603 per share, for a total transaction of £224,420. Also, insider Laura Balan Balan purchased 3,500 shares of Hikma Pharmaceuticals stock in a transaction dated Friday, August 22nd. The shares were purchased at an average price of GBX 1,821 per share, for a total transaction of £63,735. Over the last 90 days, insiders have bought 217,500 shares of company stock worth $380,015,500. Company insiders own 17.76% of the company's stock.

Hikma Pharmaceuticals Company Profile

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly.